# A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B

> **NCT05365217** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 30 (actual)

## Conditions studied

- Haemophilia B

## Interventions

- **DRUG:** Nonacog beta pegol

## Key facts

- **NCT ID:** NCT05365217
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-18
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-05-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365217, "A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05365217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*